Here are the DEF 14A proxy statements from ProKidney Corp. (PROK) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow PROK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PROK filings page.
ProKidney Corp. is holding its 2026 annual stockholder meeting on May 28, 2026 at 10:00 a.m. Eastern Time, with both a Boston in-person venue and virtual webcast access. Stockholders of record as of April 8, 2026 may vote on director elections and auditor ratification.
Three Class I directors — William F. Doyle, Alan M. Lotvin, M.D., and Brian J.G. Pereira, M.D. — are nominated for new three-year terms. Stockholders are also asked to ratify Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
The proxy describes ProKidney’s staggered eight-member board, committee structure, corporate governance guidelines, and related-party arrangements. It details 2025 executive pay, including total compensation of $2,956,447 for CEO Bruce Culleton, M.D., and outlines severance and change-in-control protections for key executives.